Sjögren's disease: a new era for clinical trials?

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele 20072, Milan, Italy; Rheumatology and Clinical Immunology, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: serena.colafrancesco@humanitasresearch.it.
² UOC di Reumatologia, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy; Saint Camillus International University of Health Science, Rome, Italy.

Comment

Serena Colafrancesco et al. Lancet. 2024.

. 2024 Aug 10;404(10452):498-499.

doi: 10.1016/S0140-6736(24)01433-8. Epub 2024 Jul 31.

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele 20072, Milan, Italy; Rheumatology and Clinical Immunology, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: serena.colafrancesco@humanitasresearch.it.
² UOC di Reumatologia, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy; Saint Camillus International University of Health Science, Rome, Italy.

No abstract available

Conflict of interest statement

SC and RP received consulting fees from Novartis for scientific boards on interleukin-1 inhibition in adult-onset Still's disease.

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.